🇺🇸 FDA
Pipeline program

AZACITIDINE, Lisaftoclax, Dummy APG-2575 oral tablets, matching APG-2575 oral tablets. strength: 200 mg/tablet., AZACITIDINE

APG2575AG301

Phase 3 small_molecule active

Quick answer

AZACITIDINE, Lisaftoclax, Dummy APG-2575 oral tablets, matching APG-2575 oral tablets. strength: 200 mg/tablet., AZACITIDINE for Acute myeloid leukemia is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Acute myeloid leukemia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials